About this item:

118 Views | 89 Downloads

Author Notes:

Address correspondence to: Andrew Jenkins PhD, Associate Professor, Departments of Anesthesiology and Pharmacology, 1510 Clifton Rd NE #5013, Atlanta GA 30322, Phone: 404 727 3910, Fax: 404 727 0365, ajenki2@emory.edu

DBR and AJ are co-inventors on United States Patent Application 20110028418 that describes the use of GABAA receptor antagonists for the treatment of excessive sleepiness and sleep disorders associated with excessive sleepiness.

Nothing to disclose for this work (see ICJME for interests not related to the current work): OAM, ST, MAJ, AFF, DB, LMT, EMH, NF, PS, PSG & JWL AJ, OAM, DBR, JWL and LMT contributed to the conception and design of the study.

OAM, ST, MAJ, AFF, AJ, PS, EMH, NF and BC were responsible for acquisition and analysis of the data.

AJ, MAJ, OAM, LMT, PSG, JWL, DBR and DB were responsible for drafting the text or preparing the figures.

BC is co-owner of Pavilion Compounding Pharmacy, LLC, which is a for-profit entity that compounds flumazenil for patient use.

Subjects:

Research Funding:

This works was supported by: NIH: GM008602 & NS007480 (OM), NS083748 (LMT) & NS089719 (DBR, AJ), Veteran’s Affairs BX001677 (PSG), the James S. McDonnell (PSG) and Mind Science (DBR) Foundations, the Australian National Health and Medical Research Council APP1058542 (JWL) and the Queensland Emory Development Alliance (AJ).

DBR & AJ report prior financial support from Balance Therapeutics.

Both have received royalty payments as part of the terms of sale of the related intellectual property to Balance Therapeutics.

Keywords:

  • Science & Technology
  • Life Sciences & Biomedicine
  • Clinical Neurology
  • Neurosciences
  • Neurosciences & Neurology
  • DIAZEPAM-BINDING INHIBITOR
  • CLINICAL-EXPERIENCE
  • HYPERSOMNOLENCE
  • CLARITHROMYCIN
  • FLUMAZENIL
  • ABSENCE

Rigor, Reproducibility, and In Vitro Cerebrospinal Fluid Assays: The Devil in the Details

Show all authors Show less authors

Tools:

Journal Title:

Annals of Neurology

Volume:

Volume 81, Number 6

Publisher:

, Pages 904-907

Type of Work:

Article | Post-print: After Peer Review

Abstract:

Divergent results and misinterpretation of non-significant findings remain problematic in science – especially in retrospective, hypothesis generating, translational research.1 When such divergence occurs, it is imperative that the cause of the divergence be established. In their recent paper in Annals of Neurology, Dauvilliers et al2 challenged our earlier finding that cerebrospinal fluid (CSF) from some patients with unexplained excessive daytime sleepiness enhances the activation of GABAA receptors (GABAA-R)3. They present data from 15 subjects in which they were unable to find evidence of enhanced activation of GABAA receptors. Here we: 1) establish how flaws in Dauvilliers’ experimental design account for this difference; 2) present new data demonstrating the robustness and reproducibility of our methods and 3) summarize the clinical promise of GABAA-R antagonism in treating IH and related disorders.

Copyright information:

© American Neurological Association

Export to EndNote